サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：細胞治療および遺伝子治療市場（疾患タイプ別市場）、2023年～2029年
市場調査レポート
商品コード
1444972

細胞治療および遺伝子治療市場（疾患タイプ別市場）、2023年～2029年

Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029
出版日: | 発行: Kalorama Information | ページ情報: 英文 270 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
細胞治療および遺伝子治療市場（疾患タイプ別市場）、2023年～2029年
出版日: 2024年04月30日
発行: Kalorama Information
ページ情報: 英文 270 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

細胞療法と遺伝子療法は現代医学のフロンティアであり、疾患の根本的な遺伝的原因を治療し、身体の免疫系を遺伝的に制御することで革命的な治療が期待されています。近年、新しい治療法が増加しており、パイプラインはこの傾向が続くことを示しています。

当レポートでは、細胞治療および遺伝子治療市場について調査し、主要製品、研究開発の動向、治療法の市場内訳、地域別市場収益の概要、競合企業の概要など、各章で調査対象疾患・病態の細胞・遺伝子・RNA治療市場の世界の動向を調査しています。

目次

第1章 エグゼクティブサマリー

第2章 細胞治療および遺伝子治療のイントロダクション

第3章 腫瘍学における細胞治療および遺伝子治療市場

  • 概要
  • がん細胞の生化学
  • がん増殖の原因
  • 環境要因、DNA、RNA
  • 細胞がん遺伝子
  • 腫瘍抑制遺伝子
  • 世界のがんの負担
  • 市場見通し
  • 主な製品
  • 研究開発の動向
  • 第III相開発
  • 細胞治療および遺伝子治療の市場内訳
  • 腫瘍細胞治療および遺伝子治療市場、がんタイプ別
  • 地域市場の概要
  • 競合の概要

第4章 神経関連疾患における細胞治療および遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
  • 第III相開発
  • 細胞治療および遺伝子治療の市場内訳
  • 地域市場の概要
  • 競合の概要

第5章 筋骨格系の疾患および障害における細胞治療および遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
  • 第III相開発
  • 細胞治療および遺伝子治療の市場内訳
  • 筋骨格細胞および遺伝子治療市場（適応症別）
  • 地域市場の概要
  • 競合の概要

第6章 皮膚科における細胞治療および遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
  • 第III相開発
  • 細胞治療および遺伝子治療の市場内訳
  • 皮膚科細胞治療および遺伝子治療市場（適応症別）
  • 地域市場の概要
  • 競合の概要

第7章 心血管疾患および血液疾患における細胞治療および遺伝子治療市場

  • 概要
  • 循環器疾患
  • 特定の血液疾患
  • 市場見通し
  • 主な製品
  • 第III相開発
  • 細胞、遺伝子、RNA治療の市場内訳
  • 心血管・血液疾患細胞治療および遺伝子治療市場（適応症別）
  • 地域市場の概要
  • 競合の概要

第8章 その他の状況における細胞治療および遺伝子治療市場

  • 概要
  • 市場見通し
  • 主な製品
  • 研究開発の動向
  • 細胞治療および遺伝子治療の市場内訳
  • 地域市場の概要
  • 競合の概要

第9章 細胞治療および遺伝子治療市場レビュー

  • 市場の影響
  • 世界の人口統計
  • コスト抑制
  • 細胞治療および遺伝子治療とウイルスベクターの不足
  • 世界市場の概要
  • 細胞治療市場と遺伝子治療市場
  • 地域市場概要
  • 米国
  • 欧州/EU
  • その他の諸国
  • 細胞治療および遺伝子治療市場における競合ランキング

第10章 市場参入企業

  • 影響を及ぼす主要企業
  • AlloSource
  • Alnylam Pharmaceuticals, Inc.
  • Amgen
  • AnGes Inc.
  • Anterogen Co Ltd.
  • Atara Biotherapeutics
  • Athersys, Inc
  • BioCardia
  • Biogen, Inc.
  • BioMarin Pharmaceuticals
  • bluebird bio, Inc.
  • BrainStorm Cell Therapeutics
  • Bristol-Myers Squibb
  • Candel Therapeutics
  • Castle Creek Biosciences
  • Celyad Oncology
  • Cook Myosite, Inc
  • Dendreon Pharmaceuticals
  • FerGene, Inc
  • Gamida Cell Ltd
  • GenSight Biologics S.A.
  • Gilead Sciences, Inc.
  • Gradalis, Inc
  • Helixmith
  • Inovio Pharmaceuticals, Inc.
  • Kiadis Pharma B.V.
  • Medeor Therapeutics
  • MEDIPOST Co, Ltd.
  • MeiraGTx
  • Mesoblast Ltd.
  • Northwest Biotherapeutics, Inc.
  • Novartis AG
  • NuVasive Biologics
  • Orchard Therapeutics
  • Orthofix
  • Osiris Therapeutics, Inc.
  • Pharmicell
  • Pluristem Therapeutics, Inc.
  • Sangamo Therapeutics
  • Sanofi
  • Sarepta
  • Sotio a.s.
  • Spark Therapeutics
  • Tessa Therapeutics, Ltd.
  • uniQure N.V.
  • Vericel Corporation
目次
Product Code: 24-015

Authoritative market research on cell therapy, gene therapy, and RNA therapy analyzing markets by disease type

Cell therapy and gene therapy represent a frontier in modern medicine, promising revolutionary treatments by treating the underlying genetic causes of disease and by genetically controlling the body's immune system. Recent years have seen an increase in new therapies and the pipeline indicates this trend will continue. A large range of therapeutic areas from oncology to cardiology have seen rapidly proliferating clinical trials. "Cell Therapy and Gene Therapy Markets (Markets by Disease Type), 2023-2029" from Kalorama Information presents the market in segments that cover market estimates and forecasts, the development pipeline, and the competitive landscape of leading providers for each therapeutic area.

The report examines global developments in cell, gene, and RNA therapy markets for the select diseases and conditions in respective chapters, including principal products, trends in research and development, market breakdown of therapies, regional market revenues summary, and competitor summary.

The following therapeutic areas are covered in individual chapters with accompanying tables and figures:

  • Oncology
  • Neurology
  • Musculoskeletal
  • Dermatology
  • Cardiology/non-oncology blood
  • Other

Scope

The report covers markets for cell therapies, gene therapies, and other various forms of RNA therapies. This report does not include RNA therapies for COVID-19 or mRNA vaccines for infectious diseases in its scope.

We are excluding mRNA-based products for infectious disease in this report because that area has largely been related to vaccines which is distinct; and partly due to the obscurity of the definition of cell and gene therapy. It will, however, be addressed in other Kalorama Information vaccine reports. RNA, antisense, and related types of therapies for other diseases are included due to the broad definition of gene therapy, including the use of nucleic acids to influence gene expression.

Note that this report also does not focus on cord blood products in the scope; these have technically been approved as cell therapy products by the FDA. There is some debate as to whether these are more akin to transplants.

Diseases are categorized into therapeutic areas primarily according to the general consensus but this is often an over-simplification; genetic diseases can become complicated to classify due to many systems being affected. In some cases, there may be inconsistencies. For example, a genetic mutation may affect the liver which results in excessive amounts of a certain molecule. This molecule then causes harm to the brain, and the condition is categorized as neurological despite the origin being in the liver.

Generally, the primary effects will first dictate the category, in combination with the condition's cause. It can be case-by-case.

Information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company reports and literature; government documents and databases; research journals and reports; and general medical and business journals. Primary research methods include telephone interviews and email correspondence with company representatives, researchers and physicians. These interviews were conducted with the purpose of capturing the perspectives from industry participants on the market opportunity and current trends. This was the basis of the formulation of forecasting models and for confirming early findings related to market potential.

The market segments provide highlights and overviews of therapies, market estimates and forecasts, and competitive situations of leading providers. The report also includes information on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed.

Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2023 and expected market for 2029. Forecasts are provided through 2029 ,and the size of each market segment refers to manufacturers' revenues.

Table of Contents

Chapter 1: Executive Summary

  • Overview
  • Scope and Methodology
  • Market Overview and Potential
    • Figure 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
    • Table 1-1: Global Cell and Gene Therapy Market, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)

Chapter 2: Introduction to Cell and Gene Therapy

  • Introduction
    • Table 2-1: Total Numbers of Approved Cell, Gene, & RNA Therapies, by Type, Q4 2022-Q1 2024 (ending March 2024), Global (count, %)
    • Figure 2-1: Share of Total Global Numbers of Approved Cell, Gene, & RNA Therapies, by Type, March 2024 (%)
  • Cell Therapy
    • CAR T
    • Stem Cells
    • Adult Stem Cells
    • Human Embryonic Stem Cells
    • Table 2-2: Adult vs. Embryonic Stem Cells
  • Gene Therapy
    • Table 2-3: Somatic vs. Germ Line Gene Therapy
  • Viral Vector System and New Developments
    • Table 2-4: Selected Examples of Viruses in Gene Therapy
    • Figure 2-2: Estimated Viral Vector Use in Commercialized Cell and Gene Therapies, by Type, 2022 (%)
  • Non-viral Systems for Transporting Genes
  • Gene Editing
  • Cell and Gene Therapy: Characteristics
    • Table 2-5: Cell Therapy vs Gene Therapy
  • Staffing
  • Manufacturing Process for CAR-T
  • Leukapheresis
  • Activation
  • Transduction
  • Expansion
  • Cell and Gene Therapy Manufacturing Processes
    • Table 2-6: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
    • Figure 2-3: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
  • Cost
  • Reimbursement
  • Logistics
  • Mergers and Acquisitions
    • Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market
  • Deals, Agreements, and Collaborations
  • Regulatory Developments
  • Fast Track
  • Orphan Drug
  • Breakthrough Therapy
  • Accelerated Approval
  • Priority Review
    • Table 2-8: Regulatory Actions and Guidelines for Cell and Gene Therapy, by Select Country
  • Individualized Gene Therapy Approval Process
  • Pipeline, Development Overview
  • Pipeline, Development Progress
    • Table 2-9: Global Cell, Gene, & RNA Therapy Clinical Trial Growth (pre-clinical I through phase III), Q4 2022-Q1 2024 ($ millions, %)
    • Figure 2-4: Global Cell, Gene, & RNA Therapy Development Progress (pre-clinical through phase III), as of March 2024
    • Table 2-10: Global Gene Therapy Pipeline, by Phase, Q4 '22-Q1 '24 (count, %)
    • Figure 2-5: Global Gene Therapy Pipeline Shares by Phase, Q1 '24 (%)
  • Pipeline by Condition and Therapeutic Area
    • Table 2-11: Global Cell, Gene, & RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous, Other), Q4 '22-Q1 '24 (count, %)
    • Figure 2-6: Global Gene Therapy Pipeline Shares, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q1 '24 (%)
    • Table 2-12: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 '22-Q1 '24 (count, %)
    • Table 2-13: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa; Other), Q4 '22-Q1 '24 (count, %)
    • Figure 2-7: Global Cell, Gene, & RNA Therapy Pipeline Excluding Pre-clinical, by Rare Disease (Amyotrophic lateral sclerosis; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, leukemia, chronic lymphocytic; Cancer, liver; Cancer, lymphoma, B-cell; Cancer, lymphoma, B-cell, diffuse large; Cancer, lymphoma, non-Hodgkin's; Cancer, lymphoma, T-cell; Cancer, mesothelioma; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Cystic fibrosis; Dystrophy, Duchenne's muscular; Hemophilia A; Hemophilia B; Retinitis pigmentosa), Q4 '22-Q1 '24 (%)
    • Table 2-14: Global Non-GM Cell Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 '22-Q1 '24 (count, %)
    • Table 2-15: Global Non-GM Cell Therapy Pipeline, by Condition/Disease (Alzheimer's disease; Arthritis, osteo; Cancer, brain; Cancer, breast; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lung, non-small cell; Cancer, melanoma; Cancer, ovarian; Cancer, solid, unspecified; Cancer, unspecified; COVID-19 complications; Diabetes, Type 1; Graft-versus-host disease; Heart failure; Hepatic dysfunction, unspecified; Infarction, myocardial; Ischemia, cerebral; Parkinson's disease; Respiratory distress syndrome, acute; Spinal cord injury), Q4 '22-Q1 '24 (count, %)
    • Table 2-16: Global Non-GM Cell Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Anal fistula; Cancer, gastrointestinal, stomach; Cancer, leukemia, acute myelogenous; Cancer, liver; Cancer, lymphoma, non-Hodgkin's; Cancer, myeloma; Cancer, ovarian; Cancer, pancreatic; Cancer, renal; Dystrophy, Duchenne's muscular; Epidermolysis bullosa; Fibrosis, pulmonary, idiopathic; Graft-versus-host disease; Huntington's disease; Myelodysplastic syndrome; Respiratory distress syndrome, acute; Retinitis pigmentosa; Spinal cord injury; Thalassemia), Q4 '22-Q1 '24 (count, %)
    • Table 2-17: Global RNA Therapy Pipeline, by Therapeutic Area (Alimentary/Metabolic, Anticancer, Anti-infective, Antiparasitic, Blood and Clotting, Cardiovascular, Dermatological, Genitourinary [including sex hormones], Hormonal [excluding sex hormones], Immunological, Musculoskeletal, Neurological, Rare Diseases, Respiratory, Sensory, Miscellaneous), Q4 '22-Q1 '24 (count, %)
    • Table 2-18: Global RNA Therapy Pipeline, by Rare Disease Targeted (Amyotrophic lateral sclerosis; Cancer, liver; Cancer, ovarian; Cancer, pancreatic; Cystic fibrosis; Dementia, frontotemporal; Dystrophy, Duchenne's muscular; Dystrophy, myotonic muscular; Fibrosis, pulmonary, idiopathic; Huntington's disease; Infection, malaria prophylaxis; Infection, rabies prophylaxis; Primary ciliary dyskinesia; Respiratory distress syndrome, acute), Q4 '22-Q1 '24 (count, %)
  • Phase III Development
    • Table 2-19: Phase III Development - Cell and Gene Therapies, Select Projects
  • End Users
  • Hospitals
  • Research Institutes
  • Wound Care Centers
  • Cancer Centers

Chapter 3: Cell and Gene Therapy Markets in Oncology

  • Overview
  • Biochemistry of Cancer Cells
  • Causes of Cancer Growth
  • Environmental Factors, DNA, RNA
    • Table 3-1: Virus Association with Human Cancer
  • Cellular Oncogenes
  • Tumor Suppressor Genes
  • Global Cancer Burden
    • Figure 3-1: Estimated Number of New Cancer Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
    • Figure 3-2: Incidence of Cancer, by Type (Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Oesophagus, Prostate, Stomach, Thyroid), 2020
    • Figure 3-3: Worldwide Distribution of Cancer Incidence, by Type (Brest, Cervix Uteri, Colorectum, Liver, Lung, Prostate, Stomach, Other Cancers), 2020
  • Market Outlook
    • Table 3-2: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)
    • Figure 3-4: Cell, Gene, & RNA Therapy Markets in Oncology, 2023-2029 ($ millions)
  • Principal Products
  • Abecma
  • APCeden
  • Breyanzi
  • Carvykti
  • CreaVax-RCC
  • Delytact
  • Gendicine
  • Imlygic
  • Immuncell-LC
  • Kymriah
  • Provenge
  • Tecartus
  • Yescarta
    • Table 3-3: Cell and Gene Therapy in Oncology
  • Trends in Research and Development
  • Phase III Development
    • Table 3-4: Select Oncology Phase III Cell, Gene, & RNA Therapy Developments, through March 2024
  • Market Breakdown of Cell and Gene Therapies
    • Table 3-5: Oncology Cell and Gene Therapy Markets, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 3-5: Oncology Cell and Gene Therapy Market Distribution, by Product Type (CAR-T, Cell Immunotherapy, Gene Therapy), 2023 (%)
  • Oncology Cell and Gene Therapy Market by Cancer Type
    • Table 3-6: Oncology Cell, Gene, & RNA Therapy Market, by Cancer Type (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Undefined Blood Cancer, Other Cancers), Estimated 2023 and Projected 2029 ($ millions)
    • Table 3-7: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)
    • Figure 3-6: Oncology Cell, Gene, & RNA Therapy Market, by General Indication (Leukemia, Lymphoma, Melanoma, Multiple Myeloma, Prostate Cancer, Other Cancers), 2023 (%)
  • Regional Market Summary
    • Table 3-8: Oncology Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 3-7: Oncology Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
  • Competitor Summary
    • Table 3-9: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
    • Figure: 3-8: Oncology Cell, Gene, & RNA Therapy Competitor Market Share, Estimated 2023 (%)

Chapter 4: Cell and Gene Therapy Markets in Neurological-Related Disorders

  • Overview
  • Market Outlook
    • Table 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)
    • Figure 4-1: Cell, Gene, and RNA Therapies in Neurological-Related Conditions, 2023-2029 ($ millions)
  • Principal Products
  • Amvuttra
  • Libmeldy/ Lenmeldy
  • NeuroNata-R
  • Onpattro
  • SKYSONA
  • Spinraza
  • Stemirac
  • Wainua
  • Zolgensma
    • Table 4-2: Cell, Gene, and RNA Therapy in Neurological Diseases and Disorders
  • Trends in Research and Development
  • Phase III Development
    • Table 4-3: Select Neurological Phase III Cell and Gene Therapy Developments, through March 2024
  • Market Breakdown of Cell and Gene Therapies
    • Table 4-4: Neurological Conditions Cell and Gene Therapy Markets, by Product Type (Cell Therapy, Gene Therapy, RNA/Antisense Therapy), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 4-2: Neurological Conditions Cell, Gene, & RNA Therapy Market Distribution, by Product Type, 2023 (%)
  • Regional Market Summary
    • Table 4-5: Neurological Conditions Cell and Gene Therapy Market, by Country/Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 4-3: Neurological Conditions Cell, Gene, & RNA Therapy Market Summary, by Geographic Region (Europe, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
  • Competitor Summary
    • Table 4-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
    • Figure 4-4: Neurological Conditions Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 ($ millions)

Chapter 5: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders

  • Overview
  • Market Outlook
    • Table 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)
    • Figure 5-1: Cell, Gene, & RNA Therapy Markets in Musculoskeletal Conditions and Disorders, 2023-2029 ($ millions)
  • Principal Products
  • AlloStem
  • Amondys
  • BIO4
  • Carticel
  • Cartiform
  • CartiLife
  • Cartistem
  • Chondron
  • Elevidys
  • Exondys
  • JACC
  • MACI
  • Ortho-ACI and Ortho-ATI
  • Ossron
  • Osteocel and Osteoplus
  • Spherox
  • Trinity Elite and Trinity Evolution
  • Vyondys
    • Table 5-2: Cell and Gene Therapies in Musculoskeletal Diseases and Disorders
  • Trends in Research and Development
  • Phase III Development
    • Table 5-3: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through March 2024
  • Market Breakdown of Cell and Gene Therapies
    • Table 5-4: Musculoskeletal Cell, Gene, & RNA Therapy Markets, by Product Type, Estimated 2023 and Projected 2029 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by Indication
    • Table 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 5-2: Musculoskeletal Cell, Gene, & RNA Therapy Market, by General Indication (Bone Defect/Damage Repair, Cartilage Defect/Damage Repair, DMD, Others [Tendon Damage, Osteoarthritis]), Estimated 2023 (%)
  • Regional Market Summary
    • Figure 5-3: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 (%)
    • Table 5-6: Musculoskeletal Cell, Gene, & RNA Therapy Market, by Country/Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)
    • Figure: 5-4: Musculoskeletal Cell and Gene Therapy Market Summary, by Geographic Region (Europe, United States, South Korea, ROW), Estimated 2023 and Projected 2029 ($ millions)
  • Competitor Summary
    • Table 5-7: Musculoskeletal Cell, Gene, & RNA Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
    • Figure 5-5: Musculoskeletal Cell, Gene, & RNA Therapy Market Shares, by Company, Estimated 2023 (%)

Chapter 6: Cell and Gene Therapy Markets in Dermatology

  • Overview
    • Table 6-1: Wound Prevalence, by Type (Skin Ulcers: Pressure Injuries, Venous Statis Ulcers, Diabetic Ulcers and Burns: Outpatient Burns, Hospitalized Burns, and Medically Treated Burns)
  • Market Outlook
    • Figure 6-1: Cell and Gene Therapy Markets in Dermatology, 2023-2029 ($ millions)
  • Principal Products
  • Adipocel
  • Apligraf
  • CureSkin
  • Dermagraft
  • Epicel
  • Grafix
  • Holoderm
  • Kaloderm
  • KeraHeal/KeraHeal-Allo
  • LaViv
  • Orcel
  • Quencell
  • RECELL
  • Rosmir
  • Stempeutics/Cutisera
  • StrataGraft
  • Stravix
  • TransCyte
  • Vyjuvek
    • Table 6-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
  • Trends in Research and Development
  • Phase III Development
    • Table 6-3: Select Dermatology Phase III Cell and Gene Therapy Developments, through March 2024
  • Market Breakdown of Cell and Gene Therapies
    • Table 6-4: Dermatology Cell and Gene Therapy Markets, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 6-2: Dermatology Cell and Gene Therapy Market Distribution, by Product Type (Stem Cells, Skin Cells, Gene/Gene-Modified Cell Therapy), 2023 (%)
  • Dermatology Cell and Gene Therapy Market by Indication
  • Regional Market Summary
    • Table 6-5: Dermatology Cell and Gene Therapy Market, by Country/Region (Asia, Europe, United States, Other Countries), Estimated 2023, Projected 2029 ($ millions)
    • Figure: 6-3: Dermatology Cell and Gene Therapy Market Summary, by Geographic Region (Asia, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
  • Competitor Summary
    • Table 6-6: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2023 ($ millions)
    • Figure: 6-4: Dermatology Cell and Gene Therapy Market Share, by Company, Estimated 2023 (%)

Chapter 7: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders

  • Overview
  • Cardiovascular Disease
  • Selected Blood Disorders
  • Market Outlook
    • Table 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)
    • Figure 7-1: Cell, Gene, and RNA Therapy Markets in Cardiovascular and Blood Disorders, 2023-2029 ($ millions)
  • Principal Products
  • Collategene
  • Hearticellgram
  • HeartSheet
  • Leqvio
  • Neovasculgen
  • Stempeucel
  • Zynteglo
    • Table 7-2: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
  • Phase III Development
    • Table 7-3: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy Developments, through Mar 2023
  • Market Breakdown of Cell, Gene, and RNA Therapies
    • Table 7-4: Cardiovascular and Blood Disorders Cell, Gene, & RNA Therapy Markets, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 7-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy, Non-GM Cell, RNA, Other Gene Therapies), 2023 (%)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication
    • Table 7-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by General Indication (Blood, Cardiac, Hypercholesterolemia, Vascular), Estimated 2023 and Projected 2029 ($ millions)
  • Regional Market Summary
    • Table 7-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Market, by Country/Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 7-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary, by Geographic Region (APAC, Europe, United States, ROW), Estimated 2023 and Projected 2029 ($ millions)
  • Competitor Summary

Chapter 8: Cell and Gene Therapy Markets in Other Conditions

  • Overview
  • Market Outlook
    • Figure 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)
    • Table 8-1: Cell and Gene Therapy Markets in Other Conditions, 2023-2029 ($ millions)
  • Principal Products
  • Alofisel
  • Cupistem
  • Givlaari
  • Glybera
  • Holoclar
  • Luxturna
  • Oxlumo
  • Rethymic
  • Strimvelis
  • Temcell/Prochymal/Ryoncil
    • Table 8-2: Cell and Gene Therapy in Other Diseases and Disorders
  • Trends in Research and Development
  • Market Breakdown of Cell and Gene Therapies
    • Table 8-3: Other Conditions Cell and Gene Therapy Markets, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 8-2: Other Conditions Cell and Gene Therapy Market Distribution, by Product Type (Cell-based Gene Therapy; RNA, Antisense Etc; Stem Cell & Other Cell Therapy; Other Gene Therapy), 2023 (%)
  • Regional Market Summary
    • Table 8-4: Other Conditions Cell and Gene Therapy Market, by Country/Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
    • Figure 8-3: Other Conditions Cell and Gene Therapy Market Summary, by Geographic Region (Europe, Japan, South Korea, United States, Other Countries), Estimated 2023 and Projected 2029 ($ millions)
  • Competitor Summary

Chapter 9: Cell and Gene Therapy Market Review

  • Market Influences
  • Global Demographics
    • Table 9-1: Global Population, through 2050 (population in millions)
    • Aging Population
    • Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
  • Cost Containment
    • Table 9-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies
  • Cell and Gene Therapy and Viral Vector Shortages
  • Global Market Summary
    • Table 9-3: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
    • Figure 9-2: Cell, Gene, and RNA Therapy Market Summary, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
    • Figure 9-3: Cell and Gene Therapy Market, Distribution of Sales, by Product Segment (Cardio/Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023
  • Cell vs. Gene Therapy Markets
    • Table 9-4: Cell, Gene, & RNA Therapy Market Summary, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023-2029 ($ millions)
    • Figure 9-4: Cell, Gene, & RNA Therapy Market, Distribution of Sales, by Method (Gene/CBG Therapy, RNA Therapy, Non-GM Cell Therapy), 2023 (%)
  • Regional Market Overview
    • Table 9-5: Cell, Gene, & RNA Therapy Market Summary, by Geographical Region (Europe, United States, Other Countries), 2023-2029 ($ millions)
  • United States
    • Table 9-6: Cell, Gene, & RNA Therapy Market Summary for United States, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
    • Figure 9-5: U.S. Cell and Gene Therapy Market, Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
    • Table 9-7: Major Cell and Gene Therapy Product Approvals, FDA
  • Europe/European Union
    • Table 9-8: Cell, Gene, & RNA Therapy Market Summary for Europe/European Union, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
    • Figure 9-6: Europe Cell and Gene Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
    • Table 9-9: Major Cell and Gene Therapy Approvals by EMA
  • Other Countries
    • Table 9-10: Cell, Gene, & RNA Therapy Market Summary for Other Countries, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023-2029 ($ millions)
    • Figure 9-7: ROW Cell, Gene, & RNA Therapy Market Distribution, by Product Segment (Cardio / Non-Oncology Blood, Dermatology, Musculoskeletal, Neurology, Oncology, Other), 2023 (%)
    • Table 9-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities
  • Competitor Ranking in Cell and Gene Therapy Markets
    • Table 9-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2023 Sales ($ millions)
    • Figure 9-8: Cell and Gene Therapy Market Share Estimates, 2023

Chapter 10: Market Participants

  • Leading Influencers
  • AlloSource
    • Table 10-1: AlloSource Corporate Summary
  • Company Summary
  • Products
  • Alnylam Pharmaceuticals, Inc.
    • Table 10-2: Alnylam Pharmaceuticals Corporate Summary
  • Company Summary
  • Products
  • Amgen
    • Table 10-3: Amgen Corporate Summary
  • Company Summary
  • Products
  • AnGes Inc.
    • Table 10-4: AnGes Corporate Summary
  • Company Summary
  • Products
  • Anterogen Co Ltd.
    • Table 10-5: Anterogen Corporate Summary
  • Company Summary
  • Products
  • Atara Biotherapeutics
    • Table 10-6: Atara Biotherapeutics Corporate Summary
  • Company Summary
  • Products
  • Athersys, Inc
    • Table 10-7: Athersys Corporate Summary
  • Company Summary
  • Products
  • BioCardia
    • Table 10-8: BioCardia Summary
  • Company Summary
  • Products
  • Biogen, Inc.
    • Table 10-9: Biogen Corporate Summary
  • Company Summary
  • Products
  • BioMarin Pharmaceuticals
    • Table 10-10: BioMarin Pharmaceuticals Corporate Summary
  • Company Summary
  • Products
  • bluebird bio, Inc.
    • Table 10-11: bluebird bio Corporate Summary
  • Company Summary
  • Products
  • BrainStorm Cell Therapeutics
    • Table 10-12: BrainStorm Cell Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Bristol-Myers Squibb
    • Table 10-13: Bristol-Myers Squibb Corporate Summary
  • Company Summary
  • Products
  • Candel Therapeutics
    • Table 10-14: Candel Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Castle Creek Biosciences
    • Table 10-15: Castle Creek Corporate Summary
  • Company Summary
  • Products
  • Celyad Oncology
    • Table 10-16: Celyad Oncology Corporate Summary
  • Company Summary
  • Products
  • Cook Myosite, Inc
    • Table 10-17: Cook Myosite Corporate Summary
  • Company Summary
  • Products
  • Dendreon Pharmaceuticals (Sanpower)
    • Table 10-18: Dendreon Corporate Summary
  • Company Summary
  • Products
  • FerGene, Inc (Ferring Pharmaceuticals)
    • Table 10-19: FerGene Corporate Summary
  • Company Summary
  • Products
  • Gamida Cell Ltd.
    • Table 10-20: Gamida Cell Corporate Summary
  • Company Summary
  • Products
  • GenSight Biologics S.A.
    • Table 10-21: GenSight Biologics Corporate Summary
  • Company Summary
  • Products
  • Gilead Sciences, Inc.
    • Table 10-22: Gilead Sciences Corporate Summary
  • Company Summary
  • Products
  • Gradalis, Inc
    • Table 10-23: Gradalis Corporate Summary
  • Company Summary
  • Products
  • Helixmith
    • Table 10-24: Helixmith Corporate Summary
  • Company Summary
  • Products
  • Inovio Pharmaceuticals, Inc.
    • Table 10-25: Inovio Pharmaceuticals Corporate Summary
  • Company Summary
  • Products
  • Kiadis Pharma B.V. (Sanofi)
    • Table 10-26: Kiadis Pharma Corporate Summary
  • Company Summary
  • Products
  • Medeor Therapeutics
    • Table 10-27: Medeor Therapeutics Corporate Summary
  • Company Summary
  • Products
  • MEDIPOST Co, Ltd.
    • Table 10-28: MEDIPOST Corporate Summary
  • Company Summary
  • Products
  • MeiraGTx
    • Table 10-29: MeiraGTxCorporate Summary
  • Company Summary
  • Products
  • Mesoblast Ltd.
    • Table 10-30: Mesoblast Corporate Summary
  • Company Summary
  • Products
  • Northwest Biotherapeutics, Inc.
    • Table 10-31: Northwest Biotherapeutics Corporate Summary
  • Company Summary
  • Products
  • Novartis AG
    • Table 10-32: Novartis Corporate Summary
  • Company Summary
  • Products
  • NuVasive Biologics
    • Table 10-33: NuVasive Biologics Corporate Summary
  • Company Summary
  • Products
  • Orchard Therapeutics
    • Table 10-34: Orchard Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Organogenesis
    • Table 10-35: Organogenesis Corporate Summary
  • Company Summary
  • Products
  • Orthofix
    • Table 10-36: Orthofix Corporate Summary
  • Company Summary
  • Products
  • Osiris Therapeutics, Inc. (part of Smith & Nephew)
    • Table 10-37: Osiris Corporate Summary
  • Company Summary
  • Products
  • Pharmicell
    • Table 10-38: Pharmicell Corporate Summary
  • Company Summary
  • Products
  • Pluristem Therapeutics, Inc.
    • Table 10-39: Pluristem Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Sangamo Therapeutics
    • Table 10-40: Sangamo Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Sanofi
    • Table 10-41: Sanofi Corporate Summary
  • Company Summary
  • Products
  • Sarepta
    • Table 10-42: Sarepta Corporate Summary
  • Company Summary
  • Products
  • Sotio a.s.
    • Table 10-43: Sotio Corporate Summary
  • Company Summary
  • Products
  • Spark Therapeutics
    • Table 10-44: Spark Therapeutics Corporate Summary
  • Company Summary
  • Products
  • Tessa Therapeutics, Ltd.
    • Table 10-45: Tessa Therapeutics Corporate Summary
  • Company Summary
  • Products
  • uniQure N.V.
    • Table 10-46: UniQure Corporate Summary
  • Company Summary
  • Products
  • Vericel Corporation
    • Table 10-47: Vericel Corporate Summary
  • Company Summary
  • Products